CPI-613

Confirm delete?

CPI-613

Zoom

Cat No: 16981

Biochemicals - Small Molecule Inhibitors

Lipoic acid (Item No. 10005728) is a natural organosulfur compound that serves as a cofactor in various complexes, including the α-ketoglutarate dehydrogenase complex, which is involved in the citric acid cycle as well as other pathways. CPI-613 is a l...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

6,8-bis[(phenylmethyl)thio]-octanoic acid

Correlated keywords:

biochemical inhibitor cancer metabolism apoptosis mitochondrial biology CPI613 inhibit ?-ketoglutarate dehydrogenase ?ketoglutarate lipoic acid analog tumor cells burst reactive oxygen species death in vivo in vitro antitumor anti-tumor apoptotic nonapoptotic pathway

Product Overview:
Lipoic acid (Item No. 10005728) is a natural organosulfur compound that serves as a cofactor in various complexes, including the α-ketoglutarate dehydrogenase complex, which is involved in the citric acid cycle as well as other pathways. CPI-613 is a lipoic acid analog that inhibits α-ketoglutarate dehydrogenase, particularly in tumor cells.{27997} At 60-240 µM, CPI-613 induces a strong mitochondrial burst of reactive oxygen species, resulting in cell death.{27997} By disrupting mitochondrial metabolism, CPI-613 demonstrates both in vitro and in vivo anti-tumor activity through both apoptotic and non-apoptotic pathways.{27998,27996,27999}

Size	5 mg
Shipping	dry ice
CAS Number	95809-78-2
Molecular Formula	C₂₂H₂₈O₂S₂
SMILES	OC(CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2)=O
Molecular Weight	388,6
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2916.39
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.